Search by Drug Name or NDC
NDC 62106-8812-04 SABAL SERRULATA 1 [hp_X]/1 Details
SABAL SERRULATA 1 [hp_X]/1
SABAL SERRULATA is a ORAL GRANULE in the HUMAN OTC DRUG category. It is labeled and distributed by Seroyal USA. The primary component is SAW PALMETTO.
Product Information
NDC | 62106-8812 |
---|---|
Product ID | 62106-8812_eced0482-2733-0eaa-e053-2995a90acc79 |
Associated GPIs | |
GCN Sequence Number | n/a |
GCN Sequence Number Description | n/a |
HIC3 | n/a |
HIC3 Description | n/a |
GCN | n/a |
HICL Sequence Number | n/a |
HICL Sequence Number Description | n/a |
Brand/Generic | n/a |
Proprietary Name | SABAL SERRULATA |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Saw palmetto |
Product Type | HUMAN OTC DRUG |
Dosage Form | GRANULE |
Route | ORAL |
Active Ingredient Strength | 1 |
Active Ingredient Units | [hp_X]/1 |
Substance Name | SAW PALMETTO |
Labeler Name | Seroyal USA |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | UNAPPROVED HOMEOPATHIC |
Application Number | n/a |
Listing Certified Through | 2023-12-31 |
Package
Package Images

NDC 62106-8812-04 (62106881204)
NDC Package Code | 62106-8812-4 |
---|---|
Billing NDC | 62106881204 |
Package | 10 TUBE in 1 CARTON (62106-8812-4) / 140 GRANULE in 1 TUBE |
Marketing Start Date | 2015-07-27 |
NDC Exclude Flag | N |
Pricing Information | N/A |
Standard Product Labeling (SPL)/Prescribing Information SPL 1bdf0063-0485-4017-e054-00144ff8d46c Details
SPL UNCLASSIFIED SECTION
SPL UNCLASSIFIED SECTION
SPL UNCLASSIFIED SECTION
SPL UNCLASSIFIED SECTION
PRINCIPAL DISPLAY PANEL
INGREDIENTS AND APPEARANCE
SABAL SERRULATA
saw palmetto granule |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
Labeler - Seroyal USA (018361118) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
SAN’UP | 401010287 | manufacture(62106-8812) |
Revised: 11/2022
Document Id: eced0482-2733-0eaa-e053-2995a90acc79
Set id: 1bdf0063-0485-4017-e054-00144ff8d46c
Version: 3
Effective Time: 20221107